Received Apr 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | B532G | LL |
patient received 3rd dose a week early and a day; This non-serious case was reported by a other health professional via sales rep and described the occurrence of drug dose administration interval too short in a 7-month-old male patient who received DTPa-HBV-IPV (Pediarix) (batch number B532G, expiry date 11-APR-2027) for prophylaxis. Previously administered products included Pediarix (received 1st dose of vaccine on an unknown date). Concomitant products included Pediarix. On 20-FEB-2025, the patient received the 3rd dose of Pediarix (left thigh). On 20-FEB-2025, an unknown time after receiving Pediarix, the patient experienced drug dose administration interval too short (Verbatim: patient received 3rd dose a week early and a day). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 09-APR-2025 The nurse had given it too soon, the second dose was given on 23rd January and the third dose was administered on 20th February 2025, a week and a day early, which led to Drug dose administration interval too short.